CSF2 and congenital rubella syndrome: 1) GM-CSF inhibition by lenzilumab enhances CART19 cell proliferation, antitumor activity, and overall survival in patient-derived xenograft model; 2) Prevents the development of CRS and significantly reduces the severity of neurotoxicity; 3) clinical study: ZUMA-19